News

BioSpace12h
Lilly Takes Four Compounders to Court for Allegedly Producing Knockoff Tirzepatide
In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...
Devdiscourse18h
Eli Lilly Intensifies Legal Battle Over Tirzepatide Knockoff Sales
Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...
Pharmaceutical Technology11h
Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing
Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...
Where Will Eli Lilly Be in 5 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...
Healio1d
Long-term weight regain minimal with tirzepatide for adults with obesity, prediabetes
Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...